Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...
Shares of CureVac are trading higher by 15% during Monday's session. The stock is gaining following a CDC report highlighting ...
CureVac recently released new clinical data. Why should investors care? Click here to find out why I am bullish on CVAC stock ...
CureVac BV (CVAC) stock saw a modest uptick, ending the day at $4.44 which represents a slight increase of $0.82 or 22.65% from the prior close of $3.62. The stock opened at $4.14 and touched a low of ...
Jefferies sees Arbutus (NASDAQ:ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE) ...
Zacks.com on MSN2d
Vaccine Stocks Jump After CDC Reports First US Bird-Flu DeathOn Monday, the U.S. Centers for Disease Control and Prevention (“CDC”) reported the first human death in the country from the H5N1 virus, also known as bird flu. Despite the death, CDC believes that ...
Novavax (NVAX) and other vaccine developers rise as Investors react to rising flu and COVID-19 cases in the U.S. Read more ...
Shares of CureVac fell by 12.3% Wednesday afternoon. The pullback may stem from profit-taking after Tuesday's strong gains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback